Latest news with #FCS
USA Today
2 days ago
- Sport
- USA Today
Iowa football QB Mark Gronowski named to 2025 Maxwell Award watch list
🏆 @mgronowski11 ➡️ 𝐌𝐚𝐱𝐰𝐞𝐥𝐥 𝐀𝐰𝐚𝐫𝐝 𝐖𝐚𝐭𝐜𝐡 𝐋𝐢𝐬𝐭@MaxwellFootball x #Hawkeyes As the 2025 college football season swiftly approaches, Iowa football's presumptive starting quarterback, Mark Gronowski, has landed himself a spot on the 2025 Maxwell Award watch list, announced by the Maxwell Football Club on Monday. The Maxwell Award is presented annually to the most outstanding player in college football. At 6-foot-3, 230 pounds, the native of Naperville, Illinois, will be in his first and final season with the Hawkeyes after transferring from South Dakota State, where he led the Jackrabbits to a pair of FCS national championships in 2022 and 2023. Gronowski was the 2023 FCS statistical leader in passing efficiency (179.67) and compiled a 49-6 career record as the Jackrabbits' starting quarterback, with the 49 wins tying for the most wins in history by an FCS quarterback. Gronowski has already won the FCS equivalent of the Maxwell Award, when he secured the 2023 Walter Payton Award with South Dakota State. The Maxwell Award has been awarded to College Football's Player of the Year since 1937 and is named in honor of Robert Maxwell for his contributions to the game as a player, sportswriter, and official. Only two Hawkeyes have ever won the high distinction in the award's history: halfback Nile Kinnick in 1939 and quarterback Chuck Long in 1985. Semifinalists for the award will be announced on Nov. 11, while finalists for the distinction will be revealed on Nov. 25. The winner will be announced on Dec. 11. While the list is quite expansive at the moment, Gronowski will have an excellent opportunity to prove he is worthy of the award with a potentially historic Iowa season on the horizon. Contact/Follow us @HawkeyesWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Iowa news, notes, and opinions. Follow Scout on X: @SpringgateNews
The Citizen
2 days ago
- The Citizen
Police hunt suspect who raped and hammered 60-year-old Free State woman in her home
The suspect allegedly raped and hit the woman on her head with a hammer, leaving her bleeding profusely. Police in the Free State are seeking information that could lead them to a suspect who raped and hammered a 60-year-old woman at her Bothaville home on Saturday. The Welkom Family Violence Child Protection and Sexual Offences Unit (FCS) is investigating a rape case following the gruesome attack that left the woman hospitalised. Woman found bleeding from the head Regional police spokesperson Sergeant Palesa Thabana said Bothaville police attended to a rape complaint at around 12.15pm on 26 July, where they found the woman bleeding profusely from the head. 'It is alleged that on the [said] date, the victim had just entered her house when she was accosted by an unknown African male who allegedly hit her three times on the head with a hammer before he allegedly raped her,' Thabana said in a statement on Monday. The woman, who was allegedly struck three times, sustained severe injuries to the head and was taken to a local hospital. However, she was subsequently transferred to another hospital in Welkom due to the severity of her injuries. ALSO READ: 'Filthiest perpetrator' handed life in jail for raping 91-year-old woman Investigations continue No arrests have been made yet, but police confiscated a hammer suspected to have been used in the assault. 'Police are urging anyone with information that could lead to the arrest of the suspect to contact Warrant Officer Anje Tait of the Welkom [FSC] on 083 279 3213, or Crime Stop 08600 10111 or, alternatively, an anonymous tip-off may be sent through the MySAPS App. More than 180 suspects arrested for rape in one week The incident comes just one day after the South African Police Service announced that 183 suspects were arrested for rape across the country over the past week. Out of the 183 suspects arrested, 67 were wanted individuals who were tracked down in different parts of the country. Police spokesperson, Amanda van Wyk, said this is one of the operations that are aimed at intensifying the police's efforts in the fight against gender-based violence and femicide. NOW READ: KZN man gets life term and more for raping and robbing elderly kin
The Citizen
4 days ago
- The Citizen
Police arrest 183 rape suspects in one week
Out of the 183 suspects arrested, 67 were wanted individuals who were tracked down in different parts of the country. The South African Police Service (Saps) has arrested 183 suspects for rape in one week across the country, while a serial rapist in KwaZulu-Natal (KZN) was sentenced to 10 life terms and 70 years in prison. Police spokesperson, Amanda van Wyk, said this is one of the operations that are aimed at intensifying the police's efforts in the fight against gender-based violence and femicide (GBVF). Out of the 183 suspects arrested, 67 were wanted individuals who were tracked down in different parts of the country. Rape related convictions made Van Wyk added that the notable convictions made during the week include the sentencing of 24-year-old Simon Makgoba, who was sentenced to one life term in prison on 15 July 2025. The Mankweng Regional Court in Limpopo found him guilty of rape and kidnapping a 19-year-old woman, and gave him an additional 15 years in prison. ALSO READ: 201 rape suspects arrested nationwide in the past 10 days Another man in Limpopo was sentenced for rape on 17 July 2025 by the Mahwelereng Regional Court. Kabelo Prince Monethe, 33, was sentenced to life imprisonment for raping of a 68-year-old woman from Mapela Ga-Chaba. KZN man on multiple counts of rape On 23 July 2025, the Nquthu Regional Court in KZN sentenced Mandlelisa Mabhale, 58, to 10 life terms and an additional 70 years in prison after he was found guilty on multiple counts of rape, sexual assault, and exposing children to pornography. Van Wyk added that the victims, who are all minors, informed investigators that the pastor lured them to his rented room at the Ndidini area, where he made them watch pornographic material, then raped them. 90-day blitz programme 'Tackling the alarming rise in gender-based violence and femicide demands a united, urgent response. To this end, the Government has launched a 90-day blitz programme, with Saps playing an active and central role,' said Van Wyk. The Family Violence, Child Protection and Sexual Offences (FCS) unit is responsible for the investigation of GBVF-related cases, sexual offences, and sexual crimes committed through electronic mediums. 'Week after week, FCS investigators' hard work, dedication, and meticulous investigations ensure that sexual predators are put behind bars with lengthy sentences.' NOW READ: Limpopo crime: Father allegedly murdered by sons, pastor arrested for rape
Cision Canada
5 days ago
- Science
- Cision Canada
Food Cycle Science Partners with Newfoundland Communities to Revolutionize Food Waste Diversion from Local Landfills
OTTAWA, ON, July 25, 2025 /CNW/ - Newfoundland is taking a bold step forward in food waste innovation through a growing partnership between local municipalities and Canadian clean-tech company Food Cycle Science (FCS). With no green bin infrastructure currently available on the island, five communities - Gander, Corner Brook, Pasadena, Conception Bay South, and Portugal Cove–St. Philip's - have launched residential food waste diversion programs using the FoodCycler ®, a countertop appliance that transforms food scraps into a dry, shelf-stable by-product that's easy to store, transport, or repurpose. These programs show how rural and remote communities can lead the way in sustainability by embracing decentralized, technology-driven solutions, without waiting for large-scale infrastructure. By offering households a simple, high-tech way to manage food waste at home, municipalities are reducing the burden on landfill systems while cutting down on hauling costs and emissions. In Gander's 200-household pilot, participating households are diverting an average of 255 kg of food waste per year, keeping the annual equivalent of 4,430 garbage bags out of the regional landfill and preventing an estimated 63.1 metric tonnes of CO₂e emissions annually. " Our FoodCycler pilot program proved that giving residents a simple way to manage food waste at home can make a big difference," said Brian Hudson, Chief Administrative Officer for the Town of Pasadena. " It takes pressure off our whole waste system - less hauling, fewer emissions, and less going to landfill. If scaled community-wide, the impact would be significant." " Partnerships with municipalities are at the heart of real progress in waste management. We're proud to have worked with over 180 communities and indigenous communities across Canada to decentralized food waste management and empower residents directly," said Christina Zardo, Director of Municipal Programs at Food Cycle Science. With FoodCycler programs now spreading across Newfoundland, even small and remote communities have a practical and forward-looking way to reduce their environmental footprint from the comfort of their own kitchens. About Food Cycle Science Food Cycle Science is a Canadian clean-tech company that designs, manufactures, and distributes food waste diversion technologies and solutions. The company owns and produces the award-winning FoodCycler ® food waste recycler, which transforms food scraps into nutrient-rich, garden-ready soil amendment. Through practical, scalable solutions, Food Cycle Science helps households, businesses, and municipalities reduce landfill waste, emissions, and disposal costs. Learn more at
Yahoo
5 days ago
- Business
- Yahoo
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
– Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission decision expected by Q4 2025 – CARLSBAD, Calif., July 25, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4 2025. "Building on the strong early launch of TRYNGOLZA in the U.S., the positive CHMP opinion advances our commitment to expand access to TRYNGOLZA globally," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "TRYNGOLZA has demonstrated significant reductions in triglycerides and substantial reductions in acute pancreatitis events with favorable safety and tolerability. With this robust clinical profile, combined with Sobi's deep commercial market expertise in FCS, TRYNGOLZA has the potential to make a meaningful difference for people living with FCS in the EU." The CHMP opinion is based on positive data from the Phase 3 Balance study, in which TRYNGOLZA demonstrated a statistically significant reduction in triglyceride levels at six months that was sustained through 12 months. Additionally, TRYNGOLZA demonstrated a substantial and clinically meaningful reduction in acute pancreatitis events over 12 months. TRYNGOLZA showed a favorable safety and tolerability profile. Study results were published in The New England Journal of Medicine (NEJM). FCS is a rare and genetic form of severe hypertriglyceridemia (sHTG) that prevents the body from breaking down fats and severely impairs the ability to remove triglycerides from the bloodstream. People with FCS often have triglyceride levels of more than 880 mg/dL (10 mmol/L), compared to normal levels of <150 mg/dL (1.7 mmol/L), and are at high risk of developing acute pancreatitis, which can be life-threatening. In the EU, FCS is estimated to impact up to 13 people per million. Sobi has exclusive rights to commercialize TRYNGOLZA in countries outside the U.S., Canada and China. As Ionis' European commercial partner for Waylivra (volanesorsen), the only medicine currently approved for FCS in the EU, Sobi will leverage existing market expertise and distribution channels to enable an effective TRYNGOLZA launch in FCS, if approved. "The approval recommendation brings us one step closer toward delivering TRYNGOLZA to people living with FCS in the EU and is a testament to our long-standing support for the FCS community," said Lydia Abad-Franch, M.D., MBA, head of research, development and medical affairs and chief medical officer, Sobi. "Patients with FCS suffer from complications such as acute pancreatitis. These are very severe events, often requiring intensive care and sometimes causing multiorgan failure as well as increasing morbidity and mortality. We believe TRYNGOLZA has the potential to be an important treatment for people living with this rare and serious disease, and we look forward to the final decision from the EC later this year." TRYNGOLZA was approved in the United States in December 2024 and granted orphan designation in the EU. Olezarsen is also being evaluated for sHTG, a serious condition defined by dangerously high triglycerides (≥500 mg/dL), and data from the Phase 3 CORE and CORE2 studies are expected in Q3 2025. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. People living with FCS are at high risk of acute pancreatitis in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About TRYNGOLZA® (olezarsen) TRYNGOLZA® is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. TRYNGOLZA® (olezarsen) is approved in the United States as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). For more information about TRYNGOLZA, visit TRYNGOLZA is not yet approved for any indication in Europe. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, olezarsen, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® and TRYNGOLZA® are trademarks of Ionis Pharmaceuticals, Inc. View source version on Contacts Ionis Investor Contact: D. Wade Walke, 760-603-2331Ionis Media Contact: Hayley Soffermedia@ 760-603-4679 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
